

## Publications (articles originaux):

1. Lescure R, Privat M, Pliquett J, Massot A, Baffroy O, Busser B, Bellaye PS, Collin B, Denat F, **Bettaieb A**, Sancey L, Paul C, Goze C, Bodio E. 2021. Near-infrared emitting fluorescent homobimetallic gold(I) complexes displaying promising in vitro and in vivo therapeutic properties. **Eur J Med Chem.** **220**:113483.
2. Dumortier C, Charlet R, **Bettaieb A**, Jawhara S. 2020. H89 Treatment Reduces Intestinal Inflammation and Candida albicans Overgrowth in Mice. **Microorganisms.** **19**:2039.
3. **Mabrouk N**, Ghione S, Laurens V, Plenchette S, **Bettaieb A**, Paul C. 2020. Senescence and Cancer: Role of Nitric Oxide (NO) in SASP. **Cancers (Basel).** **12**:1145-1164 Review.
4. Ghione S, Mabrouk N, Paul C, **Bettaieb A**, Plenchette S. Protein kinase inhibitor-based cancer therapies: Considering the potential of nitric oxide (NO) to improve cancer treatment. **Biochem Pharmacol**, Online 13 February. <https://doi.org/10.1016/j.bcp.2020.113855>
5. Florès O, Velic D, Mabrouk N, **Bettaieb A**, Tomasoni C, Robert JM, Paul C, Goze C, Roussakis C, Bodio E. Rapid Synthesis and Antiproliferative Properties of Polyazamacrocyclic Bi- and Tetra-Gold(I) Phosphine Dithiocarbamate Complexes. **ChemBiochem.** 2019 Sep 2;20(17):2255-2261
6. Bouaouiche S, Lea Magadoux L, Dondaine L, Reveneau S, Isambert N, **Bettaieb A**, Jeannin JF, Laurens V, Plenchette S. Glyceryl trinitrate-induced cytotoxicity of docetaxel-resistant prostatic cancer cells is associated with differential regulation of clusterin. **International Journal of Oncology.** 2019 Apr;54(4):1446-1456.
7. Pliquett J, Dubois A, Racœur C, Mabrouk N, Amor S, Lescure R, **Bettaieb A**, Collin B, Bernhard C, Denat F, Bellaye PS, Paul C, Bodio E, Goze C. A promising family of fluorescent water-soluble aza-BODIPY dyes for in vivo molecular imaging. **Bioconjugate Chemistry.** 2019 Apr 17;30(4):1061-1066.
8. Trommenschlager A, Chotard F, Bertrand B, Amor S, Richard P, **Bettaieb A**, Paul C, Connat JL, Le Gendre P, Bodio E. Gold(I)-Coumarin-Caffeine-Based Complexes as New Potential Anti-Inflammatory and Anticancer Trackable Agents. **ChemMedChem.** 2018 Nov 20;13(22):2408-2414.
9. Pliquett J, Amor S, Ponce-Vargas M, Laly M, Racœur C, Rousselin Y, Denat F, **Bettaieb A**, Fleurat-Lessard P, Paul C, Goze C, Bodio E. Design of a multifunctionalizable BODIPY platform for the facile elaboration of a large series of gold(i)-based optical theranostics. **Dalton Trans.** 2018 Aug 14;47(32):11203-11218.
10. Martin A, Seigneux C, Racœur C, Isambert N, Mabrouk N, Scagliarini A, Reveneau S, Arnould L, **Bettaieb A**, Jeannin JF, Paul C. Tumor-derived granzyme B-expressing neutrophils acquire antitumor potential after lipid A treatment. **Oncotarget.** 2018 Jun 19;9(47):28364-28378.
11. Bahria-Sediki I, Chebil M, Sampaio C, Martel-Franchet V, Cherif M, Zermani R, Rammeh S, Ben Ammar Gaaied A, **Bettaieb A**. Prognostic value of soluble death receptor ligands in patients with transitional cell carcinoma of bladder. **Urologia Internationalis**, 2018 100(4) 476-484.
12. Romagny S, Bouaouiche S, Lucchi G, Ducoroy P, Bertoldo JB, Terenzi H, **Bettaieb A**, Plenchette S. S-nitrosylation of cIAP1 switches cancer cell fate from TNF $\alpha$ /TNFR1-mediated cell survival to cell death. **Cancer Res.** 2018 Apr 15;78(8):1948-1957.

13. Chotard F, Dondaine L, Balan C, **Bettaieb A**, Paul C, Le Gendre P, Bodio E. Highly antiproliferative neutral Ru(II)-arene phosphine complexes. **New J Chem.** 2017 42(10);8105-8112..
14. Brahim S, Aroui S, Ali R, Jeannin JF, Kennani A, **Bettaieb A**. The combination of Bleomycin with TRAIL agonists or PKC inhibitors sensitizes solid tumor cells to BLM-mediated apoptosis: new strategies to overcome chemotherapy resistance of tumors. **Medicinal Chemistry Res** 2017 26(9): 2105-2111.
15. Trommenschlager A, Bertrand B, Chotard F, Chalumeau-Delamasure S, Dondaine L, Picquet M, Denat F, **Bettaieb A**, Le Gendre P, Dutartre P, Paul C, Goze C and Bodio E. Gold(I)-BODIPY-imidazole bimetallic complexes as new potential anti-inflammatory and anticancer trackable agents. **Dalton Transactions** 2017 46(25):8051-8056.
16. **Bettaieb A**, Paul C, Plenchette S, Shan J, Chouchane L, Ghiringhelli F. Precision medicine in breast cancer: reality or utopia? **J Transl Med.** 2017 Jun 17;15(1):139.
17. **Bettaieb A**, Paul C, Plenchette S. Exploration of Fas S-Nitrosylation by the Biotin Switch Assay. **Methods Mol Biol.** 2017; 1557:199-206.
18. Plenchette S, Romagny S, Laurens V, **Bettaieb A**. NO et cancer: itinéraire d'un agent double. **Médecine/Sciences.** 2016, Jun-Jul;32(6-7):625-33.
19. Bouaouiche S, Dubrez L, **Bettaieb A**, Plenchette S. IAPs: Mediators of Oncogenesis and Targets for Anticancer Therapy. **Crit Rev Oncog.** 2016;21(5-6):399-411.
20. Dondaine L, Escudero D, Ali M, Richard P, Denat F, **Bettaieb A**, Le Gendre P, Paul C, Jacquemin D, Goze C and Bodio E. Coumarin-phosphine-based smart probes for tracking biological relevant metal complexes: from theoretical to biological investigations. **EurJIC.** 2016 4: 545-553.
21. Burgy O, Wettstein G, Bellaye PS, Decolonne N, Racœur C, Goirand F, Beltramo G, Hernandez JF, Kenani A, Camus P, **Bettaieb A**, Garrido C, Bonniaud P.. Deglycosylated bleomycin has the antitumor activity of bleomycin without pulmonary toxicity. **Sci Transl Med.** 2016 Feb 17;8 (326): 326ra20.
22. Ben Bahria-Sediki I, Sampaio C, Chebil M, Cherif M, Zermani R, Rammeh S, Ben Ammar El Gaaied A, **Bettaieb A**.. Akt activation correlates with the tumor aggressiveness in Tunisian patients with bladder cancer. **Tumour Biol.** 2016 Jun;37(6):7873-9.
23. Ben Bahria-Sediki IB, Yousfi N, Paul C, Chebil M, Cherif M, Zermani R, El Gaaied AB, **Bettaieb A**.. Clinical significance of T-bet, GATA-3, and Bcl-6 transcription factor expression in bladder carcinoma. **J Transl Med.** 2016 May 30;14(1):144.
24. Lamrani L, Sassi N, Paul C, Yousfi N, Boucher B, Gauthier N, Labbé J, Seigneux C, Racœur C, Athias A, Guerreiro R, Vergely C, Rochette L, **Bettaieb A**, Jeannin JF.. TLR4/IFN $\gamma$  pathways induce tumor regression via NOS II-dependent NO and ROS production in murine breast cancer models. **Oncolmunology**, 2015 Dec 29;5(5):e1123369.
25. Ali M, Dondaine L, Adolle A, Sampaio C, Chotard F, Richard P, Denat F, **Bettaieb A**, Le Gendre P, Laurens V, Goze C, Paul C, Bodio E. 2015. Anticancer agents: does a phosphonium behave like a gold(I) phosphine complex? Let a "smart" probe answer! **J Med Chem.** 2015 Jun 11;58(11):4521-8.
26. Cortier M, Boina-Ali R, Racœur C, Paul C, Solary E, Jeannin JF, **Bettaieb A**. 2015. H89 enhances sensitivity of cancer cells to glyceryl trinitrate through a purinergic receptor-dependent pathway. **Oncotarget.** 2015 Mar 30;6(9):6877-86.
27. Doulain PE, Decréau R, Racœur C, Goncalves V, Dubrez L, **Bettaieb A**, Le Gendre P, Denat F, Paul C\*, Goze C\* and Bodio E\*. Towards the elaboration of new gold-based optical theranostics. **Dalton Transactions.** 2015 Mar 3; 44(11):4874-83.

28. Plenchette S, Romagny S, Laurens V, **Bettaieb A**. S-nitrosylation in TNF superfamily signaling pathway: implication in cancer. **Redox Biology**. 2015; Dec; 6:507-15.
29. Seignez C, Martin A, Rollet CE, Racoeur C, Scagliarini A, Jeannin JF, **Bettaieb A**, Paul C. 2014. Senescence of tumor cells induced by oxaliplatin increases the efficiency of a lipid A immunotherapy via the recruitment of neutrophils. **Oncotarget**, 30; 5(22):11442-51.
30. Ali-Boina R, Cortier M, Decolonne N, Racoeur-Godard C, Seignez C, Lamrani M, Jeannin JF, Paul C, **Bettaieb A**. Activation of Akt by mammalian target rapamycin complex 2 renders colon cancer cells sensitive to apoptosis induced by nitric oxide and Akt inhibitor. **J. Carcinogenesis and Mutagenesis**. 2014, 10.4172/2157-2518.S8-004.
31. Leon L, Subramaniam S, Cauvard O, Plenchette-Colas S, Paul C, Godard C, Martinez-Ruiz A, Legembre P, Jeannin JF, and **Bettaieb A**. S-nitrosylation of the death receptor Fas amplifies Fas ligand-mediated cancer cell apoptosis. **Gastroenterology** 2011, 140: 2009-2018.
32. Gautier T\*, Paul C\*, Deckert V, Desrumaux C, Klein A, Labbé J, Le Guern N, Athias A, Monier S, Hammann A, **Bettaieb A**, Jeannin JF, Lagrost L. Innate immune response triggered by triacyl lipid A is dependent on phospholipid transfer protein (PLTP) gene expression. **FASEB J**. 2010; 24: 3544-54.
33. Brahim S, **Bettaieb A**, Kenani A. Derivative of bleomycin generates less of ROS? Less of fibrosis? Alternative in the development of an efficacy anticancer therapy but less toxic. **Bull Cancer** 2010; 97: 527-34.
34. Sassi N, Paul C, Martin A, **Bettaieb A**, Jeannin JF. Lipid a-induced responses in vivo. **Adv Exp Med Biol**. 2009; 667:69-80.
35. Solier, S, De Cian, M.C, **Bettaieb, A**, Desoche, L, Solary, E, and Corcos, L. PKC zeta controls DNA topoisomerase-dependent human caspase-2 pre-mRNA splicing. **FEBS Lett**. 2008; 582: 372-8.
36. Brahim S, **Bettaieb A**, and Kenani A. Deglycosylated bleomycin triggers apoptosis in laryngeal carcinoma cells in a caspase and reactive oxygen species independent manner. **J Oral Pathol Med**. 2008; 37: 352-7.
37. Leon L, Jeannin JF, and **Bettaieb A**. Post-translational modifications induced by nitric oxide (NO): implication in cancer cells apoptosis. **Nitric Oxide** 2008; 19: 77-83.
38. Jeannin JF, Leon L, Cortier M, Sassi N, Paul C, **Bettaieb A**. Nitric oxide-induced resistance or sensitization to death in tumor cells. **Nitric Oxide** 2008; 19: 158-63.
39. Aires V, Hichami A, Filomenko R, Ple A, Rebe C, **Bettaieb A**, Khan NA. DHA induces increases in (Ca<sup>2+</sup>)<sub>i</sub> IP3 production and activates selectively PKC gamma and delta via phosphatidylserine binding site : implication in apoptosis in U937 cells. **Mol Pharmacol**. 2007 72(6):1545-56
40. Brahim S, Prévotat L, Yatouji S, Mérino D, Cortier M, Rébé C, Micheau O, Kenani A and **Bettaieb A**. Deglycosylated bleomycin induces apoptosis in lymphoma cell via c-jun NH<sub>2</sub>-terminal kinase but not reactive oxygen species. **Biochem Pharmacol.**, 2007; 10: 1445-1455.
41. Van Hoecke M, Prigent-Tessier AS, Garnier PE, Bertrand NM, Filomenko R, **Bettaieb A**, Marie C, Beley AG. Evidence of HIF-1 functional binding activity to caspase-3 promoter after photothrombotic cerebral ischemia. **Mol Cell Neurosci**. 2006; 34(1): 40-47.

42. Prévotat L, Filomenko R, Solary E, Jeannin JF, **Bettaieb A**. Nitric oxide-induced down-regulation of beta-catenin in colon cancer cells by a proteasome-independent specific pathway. **Gastroenterology**. 2006 Oct;131(4):1142-52.
43. Filomenko R, Prevotat L, Rebe C, Cortier M, Jeannin JF, Solary E, **Bettaieb A**. Caspase-10 involvement in cytotoxic drug-induced apoptosis of tumor cells. **Oncogene**. 2006 Dec 7;25(58):7635-45.
44. Gambert S, Vergely C, Filomenko R, Moreau D, **Bettaieb A**, Opie LH, Rochette L. Adverse effects of free fatty acid associated with increased oxidative stress in postischemic isolated rat hearts. **Mol Cell Biochem**. 2006 Feb;283(1-2):147-52.
45. Reis C, Giocanti N, Hennequin C, Megnin-Chanet F, Fernet M, Filomenko R, **Bettaieb A**, Solary E, Favaudon V. A role for PKCzeta in potentiation of the topoisomerase II activity and etoposide cytotoxicity by wortmannin. **Mol Cancer Ther**. 2005 Oct;4(10):1457-64.
46. Skouri H, **Bettaieb A**, Fromont P, Elomri H, Ennabli S, Bierling P. Platelet and granulocyte alloimmunisation in multitransfused Tunisian patients. **Eur J Haematol**. 2005 Sep;75(3):248-51.
47. Gauthier N, Arnould L, Chantome A, Reisser D, **Bettaieb A**, Reveneau S, Jeannin JF. [To stimulate or to inhibit nitric oxide production in mammary tumors?] **Bull Cancer** 2004 Sep;91(9):705-12.
48. **Bettaieb A**, Dubrez-Daloz L, Launay S, Plenchette S, Rebe C, Cathelin S, Solary E. Bcl-2 proteins: targets and tools for chemosensitisation of tumor cells. **Curr Med Chem Anticancer Agents**. 2003 Jul;3(4):307-18.
49. Solary E, **Bettaieb A**, Dubrez-Daloz L, Corcos L. Mitochondria as a target for inducing death in malignant hematopoietic cells. *Leukemia & Lymphoma* 2003, 44: 563-574.
50. Gati A, Guerra N, Gaudin C, Da Rocha S, Escudier B, Lecluse Y, **Bettaieb A**, Chouaib S, Caignard A. CD158 receptor controls cytotoxic T-lymphocyte susceptibility to tumor-mediated activation-induced cell death by interfering with Fas signaling. **Cancer Res**. 2003 Nov 1;63(21):7475-82.
51. Plo I, Lehne G, Beckstrom KJ, Maestre N, **Bettaieb A**, Laurent G, Lautier D. Influence of ceramide metabolism on P-glycoprotein function in immature acute myeloid leukemia KG1a cells. **Mol Pharmacol**. 2002 Aug;62(2):304-12.
52. Millet A, **Bettaieb A**, Renaud F, Prevotat L, Hammann A, Solary E, Mignotte B, Jeannin JF. Influence of the nitric oxide donor glyceryl trinitrate on apoptotic pathways in human colon cancer cells. **Gastroenterology**. 2002 Jul;123(1):235-46.
53. Filomenko R, Poirson-Bichat F, Billerey C, Belon JP, Garrido C, Solary E, **Bettaieb A**. Atypical protein kinase C zeta as a target for chemosensitization of tumor cells. **Cancer Res**. 2002 Mar 15;62(6):1815-21.
54. E Solary, **A Bettaieb**, Dubrez-Daloz L, Garido C. Implications physiopathologiques des altérations des gènes impliqués dans la régulation de la mort cellulaire. **Médecine/Sciences** 2002, 18: 861-873.
55. de Thonel A, **Bettaieb A**, Jean C, Laurent G, Quillet-Mary A. Role of protein kinase C zeta isoform in Fas resistance of immature myeloid KG1a leukemic cells. **Blood**. 2001 Dec 15;98(13):3770-7.
56. Plenchette S, Moutet M, Benguella M, N'Gondara JP, Guigner F, Coffe C, Corcos L, **Bettaieb A**, Solary E. Early increase in DcR2 expression and late activation of caspases in the platelet storage lesion. **Leukemia**. 2001 Oct;15(10):1572-81.
57. Miguet C, Monier S, **Bettaieb A**, Athias A, Bessede G, Laubriet A, Lemaire S, Neel D, Gambert P, Lizard G. Ceramide generation occurring during 7beta-hydroxycholesterol-

- and 7-ketocholesterol-induced apoptosis is caspase independent and is not required to trigger cell death. **Cell Death Differ.** 2001 Jan;8(1):83-99.
58. Dorothee G, Ameyar M, **Bettaieb A**, Vergnon I, Echchakir H, Bouziane M, Chouaib S, Mami-Chouaib F. Role of Fas and granule exocytosis pathways in tumor-infiltrating T lymphocyte-induced apoptosis of autologous human lung-carcinoma cells. **Int J Cancer.** 2001 Mar 15;91(6):772-7.
  59. Plo I, Lautier D, Levade T, Sekouri H, Jaffrezou JP, Laurent G, **Bettaieb A**. Phosphatidylcholine-specific phospholipase C and phospholipase D are respectively implicated in mitogen-activated protein kinase and nuclear factor kappaB activation in tumour-necrosis-factor-alpha-treated immature acute-myeloid-leukaemia cells. **Biochem J.** 2000 Oct 15;351 Pt 2:459-67.
  60. Allouche M, Charrad RS, **Bettaieb A**, Greenland C, Grignon C, Smadja-Joffe F. Ligation of the CD44 adhesion molecule inhibits drug-induced apoptosis in human myeloid leukemia cells. **Blood.** 2000 Aug 1;96(3):1187-90.
  61. Solary E, Dimanche-Boitrel MT, **Bettaieb A**. La trimérisation spontanée des récepteurs de la famille TNFR. **Médecine/Sciences** 2000, 11: 1247-1248.
  62. Solary E, Droin N, **Bettaieb A**, Corcos L, Dimanche-Boitrel MT, Garrido C. Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies. **Leukemia.** 2000 Oct;14(10):1833-49.
  63. Mansat-de Mas V, Bezombes C, Quillet-Mary A, **Bettaieb A**, D'orgeix AD, Laurent G, Jaffrezou JP. Implication of radical oxygen species in ceramide generation, c-Jun N-terminal kinase activation and apoptosis induced by daunorubicin. **Mol Pharmacol.** 1999 Nov;56(5):867-74.
  64. Plo I, Ghandour S, Feutz AC, Clanet M, Laurent G, **Bettaieb A**. Involvement of de novo ceramide biosynthesis in lymphotoxin-induced oligodendrocyte death. **Neuroreport.** 1999 Aug 2;10(11):2373-6.
  65. Shatrov VA, Ameyar M, Cai Z, **Bettaieb A**, Chouaib S. Methyltransferase inhibitor S-adenosyl-L-homocysteine sensitizes human breast carcinoma MCF7 cells and related TNF-resistant derivatives to TNF-mediated cytotoxicity via the ceramide-independent pathway. **Eur Cytokine Netw.** 1999 Jun;10(2):247-52.
  66. Plo I, **Bettaieb A**, Payrastra B, Mansat-De Mas V, Bordier C, Rousse A, Kowalski-Chauvel A, Laurent G, Lautier D. The phosphoinositide 3-kinase/Akt pathway is activated by daunorubicin in human acute myeloid leukemia cell lines. **FEBS Lett.** 1999 Jun 11;452(3):150-4.
  67. Sordet O, **Bettaieb A**, Bruey JM, Eymin B, Droin N, Ivarsson M, Garrido C, Solary E. Selective inhibition of apoptosis by TPA-induced differentiation of U937 leukemic cells. **Cell Death Differ.** 1999 Apr;6(4):351-61.
  68. Come MG, **Bettaieb A**, Skladanowski A, Larsen AK, Laurent G. Alteration of the daunorubicin-triggered sphingomyelin-ceramide pathway and apoptosis in MDR cells: influence of drug transport abnormalities. **Int J Cancer.** 1999 May 17;81(4):580-7.
  69. **A Bettaieb**, O Sordet, JP Belon, E Solary. Apoptose et chimiothérapie. **Bulletin du Cancer** 1999, 86 : 41-46.
  70. E Solary, **A Bettaieb**, C Garrido. L'apoptose induite par les agents cytotoxiques. **Hématologie** 1999 5: 43-52.
  71. **Bettaieb A**, Plo I, Mansat-De Mas V, Quillet-Mary A, Levade T, Laurent G, Jaffrezou JP. Daunorubicin- and mitoxantrone-triggered phosphatidylcholine hydrolysis:

- implication in drug-induced ceramide generation and apoptosis. **Mol Pharmacol.** 1999 Jan;55(1):118-25.
72. JP Jaffrézou, **A Bettaieb**, T Levade, G Laurent. Antitumor agent-induced apoptosis in myeloid leukemia cells: a controlled suicide. **Leukemia and Lymphoma** 1998, 29 : 453-463.
  73. Bruno AP, Laurent G, Averbek D, Demur C, Bonnet J, **Bettaieb A**, Levade T, Jaffrezou JP. Lack of ceramide generation in TF-1 human myeloid leukemic cells resistant to ionizing radiation. **Cell Death Differ.** 1998 Feb;5(2):172-82.
  74. Ameyar M, Atfi A, Cai Z, Stancou R, Shatrov V, **Bettaieb A**, Chouaib S. Analysis of human breast adenocarcinoma MCF7 resistance to tumor necrosis factor-induced cell death. Lack of correlation between JNK activation and ceramide pathway. **J Biol Chem.** 1998 Oct 30;273(44):29002-8.
  75. Bezombes C, Maestre N, Laurent G, Levade T, **Bettaieb A**, Jaffrezou JP. Restoration of TNF-alpha-induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the P-glycoprotein blocker PSC833. **FASEB J.** 1998 Jan;12(1):101-9.
  76. Mansat V, Laurent G, Levade T, **Bettaieb A**, Jaffrezou JP. The protein kinase C activators phorbol esters and phosphatidylserine inhibit neutral sphingomyelinase activation, ceramide generation, and apoptosis triggered by daunorubicin. **Cancer Res.** 1997 Dec 1;57(23):5300-4.
  77. Bailly JD, Skladanowski A, **Bettaieb A**, Mansat V, Larsen AK, Laurent G. Natural resistance of acute myeloid leukemia cell lines to mitoxantrone is associated with lack of apoptosis. **Leukemia.** 1997 Sep;11(9):1523-32.
  78. Mansat V, **Bettaieb A**, Levade T, Laurent G, Jaffrezou JP. Serine protease inhibitors block neutral sphingomyelinase activation, ceramide generation, and apoptosis triggered by daunorubicin. **FASEB J.** 1997 Jul;11(8):695-702.
  79. Allouche M, **Bettaieb A**, Vindis C, Rousse A, Grignon C, Laurent G. Influence of Bcl-2 overexpression on the ceramide pathway in daunorubicin-induced apoptosis of leukemic cells. **Oncogene.** 1997 Apr 17;14(15):1837-45.
  80. Cai Z, **Bettaieb A**, Mahdani NE, Legres LG, Stancou R, Masliah J, Chouaib S. Alteration of the sphingomyelin/ceramide pathway is associated with resistance of human breast carcinoma MCF7 cells to tumor necrosis factor-alpha-mediated cytotoxicity. **J Biol Chem.** 1997 Mar 14;272(11):6918-26.
  81. **A Bettaieb**, G Laurent. Apoptose induite par les agents anti-tumoraux. **Hématologie** 1997, 3 : 146-154.
  82. **Bettaieb A**, Record M, Come MG, Bras AC, Chap H, Laurent G, Jaffrezou JP. Opposite effects of tumor necrosis factor alpha on the sphingomyelin-ceramide pathway in two myeloid leukemia cell lines: role of transverse sphingomyelin distribution in the plasma membrane. **Blood.** 1996 Aug 15;88(4):1465-72.
  83. Jaffrezou JP, Levade T, **Bettaieb A**, Andrieu N, Bezombes C, Maestre N, Vermeersch S, Rousse A, Laurent G. Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. **EMBO J.** 1996 May 15;15(10):2417-24.
  84. **Bettaieb A**, Oksenhendler E, Duedari N, Bierling P. Cross-reactive antibodies between HIV-gp120 and platelet gpIIb (CD61) in HIV-related immune thrombocytopenic purpura. **Clin Exp Immunol.** 1996 Jan;103(1):19-23.
  85. Bierling P, Godeau B, Fromont P, **Bettaieb A**, Debili N, el-Kassar N, Rouby JJ, Vainchenker W, Duedari N. Posttransfusion purpura-like syndrome associated with CD36 (Naka) isoimmunization. **Transfusion.** 1995 Sep;35(9):777-82.

86. P Bierling, **A Bettaieb**, E Oksenhendler : Human immuno-deficiency virus-related immune thrombocytopenia. **Seminars in Thrombosis and hemostasis** 1995, 21 : 68-75.
87. Bierling P, **Bettaieb A**, Fromont P, Favrin M, Duedari N. Anti-GMP140 (CD62) autoantibody in a patient with autoimmune thrombocytopenic purpura. **Br J Haematol**. 1994 Jul;87(3):631-3.
88. Louache F, Henri A, **Bettaieb A**, Oksenhendler E, Raguin G, Tulliez M, Vainchenker W. Role of human immunodeficiency virus replication in defective in vitro growth of hematopoietic progenitors. **Blood**. 1992 Dec 15;80(12):2991-9.
89. **Bettaieb A**, Fromont P, Louache F, Oksenhendler E, Vainchenker W, Duedari N, Bierling P. Presence of cross-reactive antibody between human immunodeficiency virus (HIV) and platelet glycoproteins in HIV-related immune thrombocytopenic purpura. **Blood**. 1992 Jul 1;80(1):162-9.
90. Fromont P, **Bettaieb A**, Skouri H, Floch C, Poulet E, Duedari N, Bierling P. Frequency of the polymorphonuclear neutrophil Fc gamma receptor III deficiency in the French population and its involvement in the development of neonatal alloimmune neutropenia. **Blood**. 1992 Apr 15;79(8):2131-4.
91. Louache F, **Bettaieb A**, Henri A, Oksenhendler E, Farcet JP, Bierling P, Seligmann M, Vainchenker W. Infection of megakaryocytes by human immunodeficiency virus in seropositive patients with immune thrombocytopenic purpura. **Blood**. 1991 Oct 1;78(7):1697-705.
92. Godeau B, Fromont P, **Bettaieb A**, Beaujean F, Duedari N, Bierling P. Relapse of posttransfusion purpura after transfusion with frozen-thawed red cells. **Transfusion**. 1991 Feb;31(2):189-90.
93. Bettaieb A, Fromont P, Rodet M, Godeau B, Duedari N, Bierling P. Brb, a platelet alloantigen involved in neonatal alloimmune thrombocytopenia. **Vox Sang**. 1991;60(4):230-4.
94. Godeau B, Fromont P, **Bettaieb A**, Duedari N, Bierling P. [Post-transfusion purpura. An unknown cause of acute immune thrombocytopenia. 4 new cases] **Presse Med**. 1990 Dec 15;19(43):1974-7.
95. Moutet A, Fromont P, Farcet JP, Rotten D, **Bettaieb A**, Duedari N, Bierling P. Pregnancy in women with immune thrombocytopenic purpura. **Arch Intern Med**. 1990 Oct;150(10):2141-5.
96. Bierling P, Fromont P, **Bettaieb A**, Duedari N. Anti-Bra antibodies in the French population. **Br J Haematol**. 1989 Nov;73(3):428-9.
97. **Bettaieb A**, Oksenhendler E, Fromont P, Duedari N, Bierling P. Immunochemical analysis of platelet autoantibodies in HIV-related thrombocytopenic purpura: a study of 68 patients. **Br J Haematol**. 1989 Oct;73(2):241-7.
98. Kieffer N, **Bettaieb A**, Legrand C, Coulombel L, Vainchenker W, Edelman L, Breton-Gorius J. Developmentally regulated expression of a 78 kDa erythroblast membrane glycoprotein immunologically related to the platelet thrombospondin receptor. **Biochem J**. 1989 Sep 15;262(3):835-42.
99. Villeval JL, Le Van Kim C, **Bettaieb A**, Debili N, Colin Y, el Maliki B, Blanchard D, Vainchenker W, Cartron JP. Early expression of glycophorin C during normal and leukemic human erythroid differentiation. **Cancer Res**. 1989 May 15;49(10):2626-32.
100. **Bettaieb A**, Farace F, Mitjavila MT, Mishal Z, Dokhelar MC, Tursz T, Breton-Gorius J, Vainchenker W, Kieffer N. Use of a monoclonal antibody (GA3) to demonstrate lineage

restricted O-glycosylation on leukosialin during terminal erythroid differentiation. **Blood**. 1988 May;71(5):1226-33.

101. A Bettaieb, JL Villeval, N Kieffer, F Farace, L Edelman, JP Cartron, W Vainchenker. Early erythroid markers as probes for normal and leukaemic erythroid differentiation. **Ann Inst Pasteur/ Immunol** 1987, 138 : 877-883.
102. Villeval JL, Cramer P, Lemoine F, Henri A, **Bettaieb A**, Bernaudin F, Beuzard Y, Berger R, Flandrin G, Breton-Gorius J, et al. Phenotype of early erythroblastic leukemias. **Blood**. 1986 Nov;68(5):1167-74.
103. Villeval JL, Testa U, Vinci G, Tonthat H, **Bettaieb A**, Titeux M, Cramer P, Edelman L, Rochant H, Breton-Gorius J, et al. Carbonic anhydrase I is an early specific marker of normal human erythroid differentiation. **Blood**. 1985 Nov;66(5):1162-70.
104. Testa U, Henri A, **Bettaieb A**, Titeux M, Vainchenker W, Tonthat H, Docklear MC, Rochant H. Regulation of i- and l-antigen expression in the K562 cell line. **Cancer Res**. 1982 Nov;42(11):4694-700.
105. Testa U, Thomopoulos P, Vinci G, Titeux M, **Bettaieb A**, Vainchenker W, Rochant H. Transferrin binding to K562 cell line: Effect of heme and sodium butyrate induction. **Exp Cell Res**. 1982 Aug;140(2):251-60.
106. Plenchette S, Paul C, **Bettaieb A**. Nitric oxide and platinum derivatives-based regimens for cancer treatment: from preclinical studies to clinical trials. **Nitric oxide (Donor/Induced) in chemosensitizing**. 2017; Vol. 1 pages 91-103, a volume in Cancer Sensitizing Agents for Chemotherapy Edited by B Bonavida. Elsevier.
107. **Bettaieb A**, Plenchette-Colas S, Paul C, Laurens V, Jeannin JF. S-nitrosylation in cancer cell: to prevent or to cause? **Forum on immunological diseases and therapeutics**, Editor: Bonavida B, 2015. P97-109.
108. Cortier M, Leon L, Sassi N, Paul C, Jeannin JF, **Bettaieb A**. NO is a promising enhancer for cancer therapy. 2010: **Nitric Oxide and Cancer**. Editor: Benjamin Bonavida.
109. Sassi N, Paul C, Martin A, **Bettaieb A**, Jeannin JF. Lipid A-induced responses in vivo. Advances in experimental medicine and biology (volume 667): **lipid A in cancer therapy**. 2010: 69, 80. Hardcover ISBN: 978-1-4419-1602-0. Editor: Jean-François Jeannin.
110. JF, Reisser D, Leon L, **Bettaieb A**. Nitric oxide tumor cell sensitization to cell death. Hemoimmunosensitization of resistant tumor cells to cell death by apoptosis. 2006: 217-230 ISBN: 81- 895-242-4. Editor: Benjamin Bonavida.
111. **A Bettaieb**, M Titeux, P Fromont, W Vainchenker, P Bierling. Characterization of unclustered monoclonal anti-platelet antibodies of the workshop. The V<sup>th</sup> International Workshop; Boston 1993, **Human leukocyte differentiation antigens**. November 3 - 7.
112. B Godeau, P Fromont, **A Bettaieb**, N Duédari, P Bierling. Le purpura post-transfusionnel: Une cause méconnue de thrombopénie aiguë immunologique à propos de quatre nouveaux cas. **Presse Médicale** 1990, 19 : 1974 - 1977.
113. M Titeux, B Berton, A Katz, **A Bettaieb**, P Fromont, P Bierling, W Vainchenker. Characterization of the platelet antigens identified by Workshop antibodies and their reactivity with myeloid cell lines. *Leucocyte typing IV, White Cell Differentiation Antigens*. 1989, 974-977.